ABCL Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Abcellera Biologics Inc

Watchlist Manager

Watchlist

Price: 12.63 USD 0.68%

Market Cap: $3.9B

	Abcellera Biologics Inc NASDAQ:ABCL	CA
S	System and Application Technologies Inc KOSDAQ:060540	KR
	China SXT Pharmaceuticals Inc NASDAQ:SXTC	CN

Profitability Summary

Abcellera Biologics Inc's profitability score is 12/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-340%

Negative 3Y Average Operating Margin

-725%

Operating Margin is Increasing

-415% > -340%

Negative Net Margin

-249%

Negative 3Y Average Net Margin

-427%

Net Margin is Increasing

-256% > -249%

Negative Free Cash Flow Margin

-181%

Negative 3Y Average Free Cash Flow Margin

-415%

Declining Free Cash Flow Margin

-137% > -181%

Negative ROE

-17%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-30%

ROIC is Increasing

-25% > -24%

View All

Hide

Collapse

12 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.